DFDA

Extended Half-Life (EHL) Recombinant Factor VIII

Treatment for Hemophilia

Typical Dosage: Prophylaxis: 25-65 IU/kg 2 times per week or every 3-5 days; On-demand: 10-50 IU/kg

Effectiveness
90%
Safety Score
65%
Clinical Trials
2
Participants
8K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
Prophylaxis: 25-65 IU/kg 2 times per week or every 3-5 days; On-demand: 10-50 IU/kg
Time to Effect
immediate
Treatment Duration
lifetime
Evidence Quality
HIGH
Number Needed to Treat (NNT)
2(Treat 2 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
8(Treat 8 patients to see 1 additional serious adverse event)
Confidence Score
92%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$400,000
Monitoring:$5,000
Side Effect Mgmt:$8,000
Total Annual:$413,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATE
ICER
$110,000/QALY
QALYs Gained
0.35
Outcome-Based Costs
Cost per Responder
$434,736.84
Comparison vs Standard Half-Life Recombinant Factor VIII
Cost Difference
+$50,000/year
More expensive
QALY Difference
+0.05 QALYs
Better outcomes
Dominance
No dominance
Extended Half-Life (EHL) Recombinant Factor VIII Outcomes

for Hemophilia

Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+95%
Common Side Effects
Inhibitor development
+10%
Allergic reactions
+0.5%
Injection site reactions
+3%

Sources:

nih.gov
nih.gov
htct.com.br

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov

Completed Clinical Trials
2 completed trials for Extended Half-Life (EHL) Recombinant Factor VIII in Hemophilia

A Study in Children, Teenagers and Adults With Severe Hemophilia A Who Switched From Other Factor VIII Treatments to Adynovate

NCT04876365COMPLETED
View Study
153 participants
OBSERVATIONAL
Hamilton, Canada
Started: Nov 30, 2021

Pharmacokinetic Assessment of Standard Half-Life (SHL) FVIII, Extended Half-Life (EHL) FVIII, and Efanesoctocog Alfa (BIVV001) in Severe Hemophilia A

NCT05042440COMPLETEDPHASE1
View Study
13 participants
INTERVENTIONAL
Sofia, Bulgaria
Started: Aug 11, 2021